---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-030870"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2025-04-02T23:59:59+00:00"
generated_at: "2026-05-23T23:49:43.623090+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Edgewise Therapeutics prices $200M common stock offering at $20.13 per share

## Summary
- 9,935,419 shares priced at $20.13; gross proceeds ~$200M before discounts and expenses.
- Closing expected April 3, 2025; anticipated cash runway through 2028 (including existing cash).
- Proceeds to fund sevasemten for Becker/Duchenne MD, EDG-7500 HCM trials, and R&D.
- Participants include Braidwell, Cormorant, Driehaus, Invus, Janus, MPM, OrbiMed, Paradigm, Perceptive, RA Capital, Sofinnova.
- Underwritten by Leerink, Piper Sandler, Guggenheim, and Truist Securities.

## SEC filing metadata
- accession: 0001104659-25-030870
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2025-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465925030870/0001104659-25-030870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465925030870/tm2510984d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-030870
- JSON: https://secwatch.observer/filing/0001104659-25-030870.json
- Plain text: https://secwatch.observer/filing/0001104659-25-030870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.